The case for switching from animal models to organoids in preclinical testing
来源：Molecular Devices 时间：2025-07-29
The case for switching from animal models to organoids in preclinical testing
Jun 03, 2025
In her byline for Manufacturing Chemist, Mary Duseau, President of Molecular Devices, explains how recent FDA and NIH initiatives are accelerating the shift toward human-relevant models, and highlights the role of automation in making organoid development scalable and reproducible.
From toxicity testing to oncology drug discovery, Mary illustrates how organoids are helping researchers identify ineffective or unsafe compounds earlier in the pipeline, ultimately speeding up development timelines and improving patient outcomes.
